TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31623498
Drug: Rivaroxaban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (10 mg/d) following J-ROCKET AF criteria
Study: 31623498
Drug: Rivaroxaban (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (20 mg/d) and (15 mg/d)
Study: 29132740
Drug: Symbiotics (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbiotics (12 g/day of Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium bifidum, and fructooligosaccharides)
Study: 29132740
Drug: Medium absorption
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium absorption complex carbohydrate
Study: 23328338
Drug: Intravenous tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tramadol (0.1 g tid) for 3 days followed by oral tramadol (0.1 g tid) for 4 days
Study: 23328338
Drug: Intravenous parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Intravenous parecoxib (40 mg bid) for 3 days followed by oral celecoxib (0.2 mg bid) for 4 days
Study: 23328338
Drug: Intravenous parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Intravenous parecoxib (40 mg bid) for 3 days
Study: 23328338
Drug: Intravenous tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tramadol (0.1 g tid) for 3 days
Study: 17702193
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of nifuratel
Study: 17702193
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of nifuratel
Study: 15025738
Drug: Levosimendan at
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan at 0.05 micro g kg(‐1) min(‐1)
Study: 15025738
Drug: Levosimendan at
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan at 0.1 micro g kg(‐1) min(‐1)
Study: 9734737
Drug: Amino acids,
Normalized name: AMINO ACIDS, SOY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acids, glucose, and lipid infusion for 3 hours
Study: 8291598
Drug: Topical ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ofloxacin 0.3% eyedrops, six times, one drop every three hours until 90 minutes preoperatively
Study: 8291598
Drug: Topical ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ofloxacin 0.3% eyedrops, two additional instillations, one drop every 30 minutes until 30 minutes before aspiration
Study: 8291598
Drug: Oral ofloxacin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ofloxacin, single 200‐mg dose
Study: 8291598
Drug: Intravenous ofloxacin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ofloxacin, 200 mg infusion
Study: 30783328
Drug: Heparin topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin topical solution (1000 IU/ml)
Study: 30783328
Drug: Heparin topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin topical gel (200 IU/g)
Study: 24910102
Drug: Ketamine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (all doses)
Study: 14661491
Drug: Injection rate
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection rate of 5 mL/sec
Study: 14661491
Drug: All study
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All study groups with injection rates of 3 ml/sec and 5 mL/sec
Study: 14661491
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with injection rate of 3 ml/sec and 60 sec delay time
Study: 1516676
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 (methylcobalamin) 3 mg/day for 4 weeks
Study: 12266391
Drug: DIANE combined
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: DIANE combined low dose treatment (2 mgr Androcur and .05 mgr of EE in 21‐day cycles)
Study: 12266391
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose combination (50 mgr Androcur and .05 mgr of EE in 21 day cycles)
Study: 12266391
Drug: Continuous administration
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous administration of Androcur (25‐150 mgr)
Study: 12266391
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose combination
Study: 12266391
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose continuous method
Study: 12266391
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose combined method
Study: 24297946
Drug: Optimized high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized high-dose imatinib
Study: 24297946
Drug: High-dose imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose imatinib
Study: 18405790
Drug: Sequential regimen:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential regimen: pantoprazole 40 mg and amoxicillin 1 g for 7 days, followed by pantoprazole 40 mg, tetracycline 500 mg, and metronidazole 500 mg for the next 7 days.
Study: 18405790
Drug: PAC group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAC group: pantoprazole 40 mg, amoxicillin 1 g, and clarithromycin 500 mg for 14 days.
Study: 18405790
Drug: Nonsmoking patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsmoking patients in sequential group.
Study: 18405790
Drug: Smoking patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking patients in sequential group.
Study: 18405790
Drug: Sequential group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential group adverse events.
Study: 15986288
Drug: Endoscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic treatment of dominant stenoses
Study: 7815178
Drug: Zinc intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc intake (3.5 mg/d or 14.5 mg/d)
Study: 2016011
Drug: Antibiotics prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics prescribed to patients with clinical signs and symptoms of pharyngitis.
Study: 2016011
Drug: Antibiotics effective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics effective against Mycoplasma and Chlamydia.
Study: 2016011
Drug: Projected costs
Normalized name: costus root oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Projected costs of drug treatment for patients with NSP.
Study: 24256483
Drug: Automated vasopressor
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated vasopressor system (phenylephrine 50 μg or ephedrine 4 mg)
Study: 24256483
Drug: Manual boluses
Normalized name: phenylbutazone
DrugBank: Phenylbutazone (DB00812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual boluses (phenylephrine 100 μg or ephedrine 8 mg)
Study: 18544145
Drug: Ketamine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (5 mg.kg(‐1) intramuscular)
Study: 16158372
Drug: Whole Body
Normalized name: MaxiVision Whole Body Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole Body Vibration training (3 times weekly for 5 weeks, 35-40 Hz, 1.7-2.5 mm, Power Plate)
Study: 11572225
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (diode 670 nm and Helium‐Neon 632.8 nm) at frequencies of 5 Hz, 292 Hz, and 9,000 Hz
Study: 11572225
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (nonlaser therapy)
Study: 9197961
Drug: Moisturizing cream
Normalized name: MOISTURIZING CREAM
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moisturizing cream (test cream)
Study: 8457531
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (70 mg Zn twice weekly for 1.25 years)
Study: 3537626
Drug: Stim‐O‐Stam (acute:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stim‐O‐Stam (acute: 1.24 g one hour before exercise)
Study: 3537626
Drug: Stim‐O‐Stam (chronic:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stim‐O‐Stam (chronic: 3.73 g X d‐1 for 6 d prior to exercise)
Study: 21627741
Drug: Reflux symptoms
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reflux symptoms (never, monthly or less often, weekly or more often)
Study: 28693594
Drug: Perioperative infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative infusion regime with sodium glycerophosphate and Jonosteril®
Study: 25294611
Drug: Budesonide (BUD,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (BUD, inhaled)
Study: 25294611
Drug: Budesonide/formoterol (BUD/FM,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol (BUD/FM, inhaled)
Study: 25294611
Drug: Procaterol tablet
Normalized name: procaterol
DrugBank: Procaterol (DB01366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaterol tablet (PT)
Study: 24848284
Drug: Tapentadol ER
Normalized name: tapentadol Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol ER (100‐250 mg bid)
Study: 19782476
Drug: Single nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single nasal testosterone dose
Study: 17376106
Drug: Concurrent symptoms
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent symptoms with headache
Study: 2136968
Drug: Intravenous isradipine
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous isradipine (0.01 mg/kg, n = 16)
Study: 23901266
Drug: Integrative Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative Medicine (IM) program
Study: 16002021
Drug: Reinforcement-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinforcement-based therapy (RBT)
Study: 7966041
Drug: Oral ketoconazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketoconazole, 400 mg daily for 14 days
Study: 7966041
Drug: Clotrimazole vaginal
Normalized name: Clotrimazole Vaginal Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole vaginal suppositories, 100 mg daily for 7 days
Study: 12418395
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of beta-interferon used every other day
Study: 27884047
Drug: Attention control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention control (oral health)
Study: 27703286
Drug: Cisatracurium (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium (0.2 mg/kg)
Study: 22325844
Drug: Thrice-weekly intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly intensive phase therapy
Study: 22325844
Drug: Daily intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intensive phase therapy
Study: 16002932
Drug: Levofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (500 mg IV, q12h)
Study: 16002932
Drug: Cefotaxime (1g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (1g IV, q8h) + Ofloxacin (200 mg IV, q12h)
Study: 10604046
Drug: Peppermint oil
Normalized name: Peppermint Oil
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peppermint oil and caraway oil combination preparation (PCC, Enteroplant)
Study: 7791267
Drug: MND-21 (2.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MND-21 (2.7 g EPA‐E) daily for 12 weeks
Study: 7791267
Drug: MND-21 (2.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MND-21 (2.7 g EPA‐E) for 4 weeks
Study: 7791267
Drug: MND-21 (2.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MND-21 (2.7 g EPA‐E) for 2 months
Study: 6820891
Drug: Levamisole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (150 mg daily for 3 consecutive days before surgery, repeated every fortnight for one year after surgery)
Study: 6820891
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (20 mg day 0, 10 mg day 1, one shot i.v.) and 5-FU (150 mg/day, p.o.)
Study: 31030167
Drug: Walnuts (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnuts (40 g/day for 4 weeks)
Study: 24452849
Drug: sitagliptin 50-100
Normalized name: SITagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sitagliptin 50-100 mg/day
Study: 22081052
Drug: Rikkunshito (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rikkunshito (7.5 g/day) with a standard dose of RPZ (10 mg/day)
Study: 22081052
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of RPZ (20 mg/day)
Study: 11465651
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg + HCTZ 12.5 mg/day
Study: 11465651
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg + Benazepril 20 mg/day
Study: 7917736
Drug: Atracurium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium infusion with prior administration of suxamethonium
Study: 7917736
Drug: Atracurium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium infusion without prior administration of suxamethonium
Study: 3294318
Drug: Antibiotic/steroid ear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic/steroid ear drops
Study: 3294318
Drug: Active therapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active therapy (antibiotic/steroid ear drops)
Study: 3294318
Drug: Gentamicin (antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (antibiotic used in active therapy)
Study: 28810284
Drug: Systemic corticosteroid
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic corticosteroid therapy (initial dose of 80 mg prednisolone for 2 weeks, tapered over 3 to 4 months)
Study: 25724322
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise intervention comprising twice-weekly exercise classes of one hour duration for 4 months, including aerobic exercise at moderate intensity and resistance exercise using weight vests, weight belts, and dumbbells.
Study: 23543804
Drug: NSF-3 (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSF-3 (one tablet at bedtime for two weeks)
Study: 23543804
Drug: Zolpidem (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (one 10 mg tablet at bedtime for two weeks)
Study: 21903982
Drug: Adjusted-dose warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted-dose warfarin (target international normalized ratio 2 to 3)
Study: 21903982
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg) plus fixed, low-dose warfarin
Study: 17097957
Drug: Tacrolimus (Tac)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (Tac) at 0.15 mg/kg/d
Study: 15337012
Drug: Maximal medication
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal medication (Control)
Study: 8826889
Drug: rh alpha‐2b‐interferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: rh alpha‐2b‐interferon (IFN) at a dose of 3 mU three times per week, given concurrently with VAD (VIC)
Study: 8826889
Drug: rh alpha‐2b‐interferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: rh alpha‐2b‐interferon (IFN) at a dose of 3 mU three times per week, given as maintenance after completion of VAD (VIF)
Study: 1533166
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural analgesia (TEA) with continuous high TEA using 0.125% bupivacaine plus sufentanil (0.05 mL/cm body length/hr)
Study: 1533166
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia (GA) with IV administration of nicomorphine (0.1 mg/kg every 6 hours)
Study: 3909977
Drug: Ethyl clofibrate
Normalized name: Ethyl clofibrate
DrugBank: Clofibrate (DB00636)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethyl clofibrate (100 mg/kg, single oral dose between 24th and 48th hour of life)
Study: 28514601
Drug: Mepolizumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab (300 mg subcutaneously every 4 weeks for 52 weeks)
Study: 26289355
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg MAS‐XR
Study: 26289355
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg MAS‐XR
Study: 23073140
Drug: Lodenafil carbonate
Normalized name: Lodenafil carbonate
DrugBank: Lodenafil carbonate (DB11927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lodenafil carbonate (1 mg - 100 mg single oral doses)
Study: 19038525
Drug: Individual Drug
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual Drug Counseling (IDC) + Group Drug Counseling (GDC) for 3 months
Study: 19038525
Drug: Group Drug
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Drug Counseling (GDC) alone for 3 months
Study: 17235504
Drug: Pegfilgrastim 6
Normalized name: PEGFILGRASTIM 6MG/0.6ML DELIVERY KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegfilgrastim 6 mg subcutaneously after R-CHOP-14
Study: 15387326
Drug: Broccoli sprouts
Normalized name: broccoli sprout extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broccoli sprouts (14, 28, or 56 g) twice daily for 7 days
Study: 12044300
Drug: IFN‐alpha‐n1 [INS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐alpha‐n1 [INS] (two tablets of 200 IU each, given sublingually once daily for eight months)
Study: 8983878
Drug: Peptide diet
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide diet or oral prednisolone
Study: 1661630
Drug: otilonium bromide
Normalized name: otilonium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: otilonium bromide (OB) 40mg tid and normal diet (10‐15 g of fibers)
Study: 1661630
Drug: high content
Normalized name: Glycerin 6.0 g in 120 mL TOPICAL LOTION [SNAIL BEE HIGH CONTENT 120mL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: high content of roughage diet (20 g of fibers) and 10 g of bran
Study: 4076325
Drug: Verapamil (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (up to 120 mg t.i.d.)
Study: 29264689
Drug: Morning (AM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning (AM) administration of gonadotropins (uFSH and hMG)
Study: 29264689
Drug: Evening (PM)
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening (PM) administration of gonadotropins (uFSH and hMG)
Study: 20811348
Drug: Supratherapeutic doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supratherapeutic doses of AZD3480 (10- and 50-fold higher exposures than a 20-mg dose)
Study: 20811348
Drug: Supratherapeutic doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supratherapeutic doses of AZD3480 and 20-mg dosing
Study: 20811348
Drug: Supratherapeutic doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supratherapeutic doses of AZD3480
Study: 18985291
Drug: Cognitive functioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive functioning assessed by the Trail-Making Test B at the onset of long-term treatment
Study: 18985291
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of neuropsychological and psychopathological variables
Study: 16162695
Drug: Regular albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular albuterol nebulizations every 4 hours
Study: 16162695
Drug: Ad-lib albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad-lib albuterol nebulizations (saline solution nebulizations every 4 hours)
Study: 1476278
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg sublingual) + 100 mg oral hydroxyzine
Study: 1476278
Drug: Control (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (100 mg oral hydroxyzine)
Study: 6097521
Drug: Clonidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (2 x 0.05 mg/day) and low-dose conjugated estrogens (0.6 mg/day)
Study: 6097521
Drug: Higher dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dosage estrogens (1.25 mg/day)
Study: 27048170
Drug: BAN2401 (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAN2401 (0.1 mg/kg to 10 mg/kg biweekly for four months)
Study: 22794216
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 17% EDTA for 10 minutes + 10 mL of 1% NaOCl for 1 minute
Study: 22794216
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 5% EDTA for 10 minutes + 10 mL of 1% NaOCl for 1 minute
Study: 22794216
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 17% EDTA for 1 minute + 10 mL of 1% NaOCl for 1 minute
Study: 22794216
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 5% EDTA for 1 minute + 10 mL of 1% NaOCl for 1 minute
Study: 22794216
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL distilled water for 10 minutes
Study: 17699836
Drug: Mixed DTPa-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed DTPa-based and Hib vaccines
Study: 17699836
Drug: Mixed DTPw-based
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed DTPw-based and Hib vaccines
Study: 17699836
Drug: DTPa-based/Hib combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa-based/Hib combination vaccines
Study: 12047324
Drug: LAM group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAM group (30 mg of lansoprazole once daily, 500 mg of amoxicillin and 250 mg of metronidazole thrice daily for 2 weeks)
Study: 12047324
Drug: LAMP group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAMP group (same as LAM group plus 18,000 tyrosine units of pronase thrice daily for 2 weeks)